31 completed, 13 active not recruiting, 5 recruiting, 2 not yet recruiting. 41 Phase 2, 15 Phase 1.
Follow Recurrent Osteosarcoma: new trials by email Literature Review of Recurrent Osteosarcoma trials Research Report on Recurrent Osteosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial FH FOLR1 ST CAR T-cells, Leukapheresis, Fludarabine - Advanced Osteosarcoma, Recurrent Osteosarcoma | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 30 | 2026-01-16 | 2026-09-01 |
| IM83 Clinical Study of CAR-T Cell Therapy in Patients With Relapsed or Refractory Osteosarcoma IM83 CAR-T Cells - Refractory Osteosarcoma, Recurrent Osteosarcoma | Phase 1 | Unknown | Beijing Immunochina Medical Science & Technology Co., Ltd. | 9 | 2024-06-15 | 2024-05-14 |
| Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation multi-kinase inhibitors in combination with bevacizumab - Liver Transplant; Complications, Hepatocarcinoma | Phase 2 | Not yet recruiting | Peking Union Medical College Hospital | 88 | 2023-09-01 | 2023-09-18 |
| Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study Atezolizumab, Cabozantinib - Locally Advanced Osteosarcoma, Metastatic Osteosarcoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 40 | 2023-04-25 | 2026-10-06 |
| Registry For Children, Adolescents And Adults With Osteosarcoma And Biologically Related Bone Sarcomas Osteosarcoma, Bone Tumor | Not yet recruiting | Klinikum Stuttgart | 1000 | 2022-09-01 | 2022-08-25 | |
| Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma | Phase 1 | Suspended | National Cancer Institute (NCI) | 73 | 2022-01-25 | 2026-08-05 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - High Risk Neuroblastoma, Recurrent Neuroblastoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 12 | 2021-08-31 | 2026-06-30 |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Onivyde, Talazoparib, Temozolomide - Recurrent Solid Tumor, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 90 | 2021-06-09 | 2026-05-19 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor Biospecimen Collection, Computed Tomography, Echocardiography Test - Desmoplastic Small Round Cell Tumor, Osteosarcoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 55 | 2021-03-08 | 2026-10-28 |
| Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma Durvalumab, Oleclumab - Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 75 | 2020-11-26 | 2026-11-03 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
| Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma Docetaxel, Gemcitabine, Hydroxychloroquine - Recurrent Osteosarcoma, Refractory Osteosarcoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 31 | 2019-01-28 | 2026-05-14 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-09-21 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Aldesleukin, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1 - Bone Sarcoma, Dedifferentiated Chondrosarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2018-04-27 | 2026-05-22 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan - Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 13 | 2018-04-17 | 2026-10-28 |
| Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Laboratory Biomarker Analysis, Pepinemab, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 26 | 2018-01-31 | 2024-07-15 |
Showing 20 of 56. Sign in to see all of them.
Osteosarcoma (56) · Neuroblastoma (27) · Neuroectodermal Tumors, Primitive, Peripheral (26) · Sarcoma (23) · Rhabdomyosarcoma (19) · Wilms Tumor (19) · Hepatoblastoma (18) · Medulloblastoma (15) · Lymphoma, Non-Hodgkin (14) · Sarcoma, Ewing (13) · Rhabdoid Tumor (12) · Ependymoma (11) · Glioma (11) · Histiocytosis, Langerhans-Cell (11) · Central Nervous System Neoplasms (7)
Neoplasms by Histologic Type (56) · Neoplasms, Bone Tissue (56) · Neoplasms, Connective Tissue (56) · Neoplasms, Connective and Soft Tissue (56) · Neoplasms (55) · Neoplasms, Glandular and Epithelial (34) · Sarcoma (33) · Neoplasms, Germ Cell and Embryonal (32) · Neoplasms, Nerve Tissue (32) · Neoplasms, Neuroepithelial (31) · Neuroectodermal Tumors (31) · Neuroectodermal Tumors, Primitive (31) · Neoplasms by Site (28) · Neoplasms, Complex and Mixed (22) · Female Urogenital Diseases (21)
Magnetic Resonance Spectroscopy (8) · Specimen Handling (8) · X-Rays (7) · Biopsy (6) · Phantoms, Imaging (6) · Nuclear Medicine Department, Hospital (4) · Cyclophosphamide (3) · cabozantinib (3) · cixutumumab (3) · CTLA-4 Antigen (2) · Ipilimumab (2) · Irinotecan (2) · LY3023414 (2) · Nivolumab (2) · Oxaliplatin (2)
National Cancer Institute (NCI) (33) · Children's Oncology Group (10) · M.D. Anderson Cancer Center (4) · Beijing Immunochina Medical Science & Technology Co., Ltd. (1) · Fred Hutchinson Cancer Center (1) · Klinikum Stuttgart (1) · Memorial Sloan Kettering Cancer Center (1) · Northwestern University (1) · Peking Union Medical College Hospital (1) · St. Jude Children's Research Hospital (1) · University of Florida (1) · Wake Forest University Health Sciences (1)
United States (51) · Puerto Rico (14) · Canada (13) · Australia (6) · China (2) · France (1) · New Zealand (1)
Katherine A Janeway (2) · Amir A Jazaeri (1) · Andrea T Franson (1) · Antoine Italiano (1) · Brenda Weigel, MD (1) · Brigitte Widemann (1) · Ching C Lau (1) · Christine A Pratilas (1) · Crystal L Mackall (1) · Damon R Reed (1) · Donald W Parsons (1) · Elizabeth D Alva (1) · Emily G Greengard (1) · Filemon Dela Cruz, MD (1) · James Whitlock (1)
PMID 31401903, PMID 22347360, PMID 23477833, PMID 30777875, PMID 31586757, PMID 32078813, PMID 32192573, PMID 33591402, PMID 34435684, PMID 34486544, PMID 35353553, PMID 38520670, PMID 38815151, PMID 38935895, PMID 39298716, PMID 41166674, PMID 42131734, PMID 42686334, PMID 42853672, PMID 42867148
U10CA180886 (16), U10CA098543 (11), UM1CA228823 (4), U01CA097452 (3), P30CA008748 (2), U01CA069856 (2), UM1CA097452 (2), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM00100 (1), N01CM62206 (1), P30CA015704 (1), P30CA016672 (1), P30CA060553 (1)